<DOC>
	<DOC>NCT00690079</DOC>
	<brief_summary>The study is being performed in order to learn more about the safety and tolerability of AZD1386. AZD1386 is primary intended for treatment of chronic pain.</brief_summary>
	<brief_title>Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<criteria>Healthy Caucasians, males or females aged ≥20 and ≤ 45 years or between 65 80 years. Female subjects must be surgically sterile or postmenopausal for at least 12 months prior to the enrolment visit. Body Mass Index (BMI) of ≥18 to ≤ 30 kg/m2 and weight of ≥50 to ≤100 kg Clinically normal physical findings including heart rate &gt; 45 bpm and laboratory values and normal resting ECG History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study. History of severe allergy/hypersensitivity or symptoms/signs of ongoing allergy/hypersensitivity. Subjects with a high decrease in blood pressure within 5 minutes when going from a supine to standing position.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>MAD</keyword>
	<keyword>Multiple ascending dose</keyword>
	<keyword>Chronic pain</keyword>
	<keyword>pain</keyword>
</DOC>